California Enacts Landmark Legislation for Scalp Cooling Coverage
California has become the largest U.S. state to mandate insurance coverage for FDA-cleared scalp cooling systems, marking a significant shift in cancer care accessibility. Assembly Bill 1682, signed by Governor Gavin Newsom on September 27, requires large-group commercial insurers and Medi-Cal to cover the cost of automated scalp cooling for patients undergoing chemotherapy. The law, set to take effect January 1, 2027, establishes a precedent for evidence-based coverage of a treatment that reduces chemotherapy-induced hair loss, a distressing side effect for many cancer patients.
California Sets New Standard for Scalp Cooling Coverage
AB 1682 defines covered scalp cooling as devices cleared by the U.S. Food and Drug Administration (FDA), ensuring treatments meet rigorous safety and efficacy standards. This statutory framework aligns with recommendations from the National Comprehensive Cancer Network (NCCN), which categorizes scalp cooling as a Category 2A treatment option for eligible patients. The legislation also includes provisions to limit out-of-pocket costs for patients, addressing a key barrier to access.
The California Health Benefits Review Program (CHBRP) conducted an independent analysis concluding that FDA-cleared scalp cooling systems effectively reduce hair loss without increasing the risk of scalp metastasis. This review informed the bill’s language, which now serves as a model for other states considering similar policies. California joins New York, Louisiana, Maryland, West Virginia, and Connecticut in enacting coverage mandates, with several additional states exploring similar measures.
Impact on Patients and Providers
Historically, scalp cooling in the U.S. has operated under a patient self-pay model, requiring individuals to cover costs directly or seek reimbursement. AB 1682 changes this dynamic by integrating scalp cooling into insurance reimbursement pathways. Three Category I CPT® codes for mechanical scalp cooling, effective January 1, 2026, now allow providers to bill insurers directly, streamlining the process for both patients and healthcare facilities.
Paxman, a manufacturer of scalp cooling systems, reported increased reimbursement consistency in states with coverage mandates, such as New York and Louisiana. The company’s Insurance-Based Billing Model enables cancer centers to administer scalp cooling as part of chemotherapy treatment, reducing upfront financial burdens for patients. This approach also provides a standardized pathway for providers to access the clinical resources needed to deliver the service.
Industry Response and Broader Implications
Richard Paxman, CEO of Paxman, emphasized the legislation’s role in expanding equitable access to cancer care. “Meaningful patient access means more than making treatment available; it means ensuring that people can benefit from it regardless of their financial circumstances,” he stated. The bill builds on California’s existing infrastructure, where over 45 cancer centers already offer Paxman and DigniCap Scalp Cooling Systems.
By linking coverage to FDA-cleared devices and established CPT codes, AB 1682 provides a replicable framework for policymakers. Paxman plans to engage with legislators in other states to advance similar initiatives, using California’s model to address disparities in access to supportive cancer care.